Schedule

Pre-congress Workshop at the Thai Red Cross Society (Thermo Fisher)

Time	Subject	Room
8.30-10.00	MagSort workshop • (Pre-Registration required)	HLA Lab at 3^rd floor, National Blood Centre Thai Red Cross Society
10.00-10.20	Break	Chumphot 1-2 Lecture Hall at 9^th floor, National Blood Centre Thai Red Cross Society (120 seats)
10.20-10.30	Welcome
10.30-12.30	Pre-Transplant Session: • Investigating complex antibody patterns using Single Antigen with MagSort • Case Study Presentations
12.30-13.00	Understanding Epitopes and making better decisions with HLA MatchMaker
13.00-13.45	Lunch
13.45-15.45	Post-Transplant Session: • Non-invasive biomarker monitoring using Cell Free DNA • Case Study Presentations
15.45-16.00	Break
16.00-17.30	Cell Free DNA workshop • (Pre-registration required)	HLA Lab at 3^rd floor, National Blood Centre Thai Red Cross Society

Time

Subject

Room

7.00-8.30

Registration Open

8.15-8.30

Opening Ceremony

Program supported by Thailand Hub of Talents in Cancer Immunotherapy, (TTCI)

8.30-10.00

Plenary Session 1: Cellular Immunotherapy I

• Role of HSCT vs CAR T cells in Hematologic Malignancy
A/Prof. Kitsada Wudhikarn, Division of Hematology, Faculty of Medicine, Chulalongkorn University, Thailand

• Challenges in delivering cellular therapies for transplant recipients and cancer patients
Prof. Rajiv Khanna, Co-Director, Queensland Immunology Research Centre; Distinguished Scientist, Tumour Immunology Laboratory, QIMR Berghofer Medical Research Institute, Australia

• mRNA-based T cell engineering for treatment of virus-related cancer and virus infection
Prof. Antonio Bertoletti, Duke-NUS Graduate Medical School, Singapore

10.00-10.30

Coffee Break with Poster Session I

10.30-12.00

Plenary Session 2: Cellular Immunotherapy II

• Clinical Application of Mesenchymal Stem Cells: Current Trends and Future Directions
Prof. Jacques Galipeau, Associate Dean for Therapeutics Development University of Wisconsin School of Medicine and Public Health, University of Wisconsin in Madison, USA

• T cell receptors and MHC diversity in risk, prognosis, and therapy for gliomas
Asst. Prof. Gary Kohanbash, Director, PNIO Laboratory, Faculty of the Department of Neurological Surgery at UPMC Children’s Hospital of Pittsburgh, USA

• Novel pans solid tumor CAR T cells and first in human trial in DIPG
Assoc. Prof. Supannikar Tawinwung, Cellular Immunotherapy Research Unit, Chulalongkorn University; Facility Director, Cell and Gene Therapy Manufacturing Center, King Chulalongkorn Memorial Hospital, Thailand

12.00-13.00

Lunch

13.00-13.30

Sponsor Session I (Care Dx)

• Advancements in HLA loci and Permissive vs. Non-permissive Mismatches

13.30-14.00

Sponsor Session II (Gen Dx)

• Revolutionizing Rapid High Resolution HLA Typing with NGS-Turbo® and NGS-Pronto® using Oxford Nanopore Technologies sequencing

14.00-14.30

Short Oral Presentation I

• Anti-TROP2 CAR-T cells secreting anti-NECTIN2 scFv effectively kill high TROP2 and NECTIN2 breast cancer cells
Dr. Suyanee Thongchot, Mahidol University, Thailand

• HLA-E triggers carcinogenesis in cervix
Prof. Ritu Aggarwal, Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

• Workup and validation of high throughput method for HLA high resolution allelic genotyping, ABO typing and CMV IgG status
Assoc. Prof. Abha Chopra, Murdoch University, Australia

14.30-16.00

Coffee Break with Poster Session I

14.00-16.30

Concurrent Workshop I (Hillgene/BKGI)

14.30-15.00	Navigating Regulatory CMC Challenges in Advanced Therapies Dr. Yuan Zhao (CTO of Hillgene)
15.00-15.30	International Perspective for Research and Development Strategies of Cell Drugs Dr. Dan Zhang (Co-Founder &Co-COB of Hillgene)
15.30-16.00	BCMA CAR-T on Clinical Application and Technological Development Trends Dr. Jishuai Zhang (Chief Technical Officer of PREGENE)
16.00-16.30	Round table discussion and Networking: The Present and Future of Cell Therapeutics in Diversity Disease Treatment Applications

1201

18.00-21.00

Welcome Reception
(Mandarin Hotel, Managed by Center Point)

Time

Subject

Room

8.30-10.00

Plenary Session 3: Haematopoietic Stem Cell Transplantation

• HSCT: An update
Dr. Dianne De Santis, PhD, FFSc (RCPA) Clinical Scientist Department of Clinical Immunology, PathWest, Fiona Stanley Hospital Adjunct Senior Teaching Fellow, University of Western Australia

• Saving Lives Across Borders: The Asia-Pacific Unrelated Stem Cell Donor Registry Experience
Pawinee Kupatawintu, National Blood Center, the Thai Red Cross Society, Thailand
Prof. Ram Mohan Jaiswal, Mahatma Gandhi Medical College & Hospital, India
Garth Healey, Australian Bone Marrow Donor Registry, Australia

10.00-10.30

Coffee Break with Poster Session II

10.30-12.00

Plenary Session 4: HLA Genomics and Clinical Relevance

• HLA in Diseases Susceptibility and Personalized Medicine
Prof. Katsushi Tokunaga, Director, Genome Medical Science Project, Research Institute,
National Center for Global Health and Medicine (NCGM); Director,
Central Biobank, National Center Biobank Network (NCBN), Japan

• Clinical implementation of HLA long-read sequencing
A/Prof. Pajaree Chariyavilaskul, Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Thailand

• HLA Typing and Beyond with Nanopore Sequencing
Dr. Thidathip Wongsurawat, Head Division of Medical Bioinformatics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

• Beyond Traditional HLA Typing: NGS and HLA Imputation for Comprehensive Analysis of HLA Alleles in Thai SLE Patients
Dr. Charles Khor Seik-Soon, Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore

12.00-13.00

Lunch

13.00-13.30

Sponsor Session III (Thermo Fisher): Development and Validation of a High-Throughput Method for HLA High-Resolution Allelic Genotyping, ABO Typing, and CMV IgG Status Detection

13.30-14.00

Sponsor Session IV (TBG): HLA Typing using Nanopore with Automation

14.00-14.30

Short Oral Session II

• HLA Diversity & DSA in Australian Donors
Mr. Steven Hiho, Australian Red cross Lifeblood, Australia

• Lnc RNAs may predict allograft rejection
Dr. Uma Kanga, All India Institute of Medical Sciences, India

• Characterisation of the Human Blood Group using third-generation sequencing
Dr. Fredrick Mobegi, Department of Clinical Immunology, PathWest Laboratory Medicine WA, Fiona Stanley Hospital Network, Australia

14.30-16.00

Coffee Break with Poster Session II

14.00-16.30

Concurrent Workshop II (Werfen)

• Werfen HLA Innovation Station

14.00–14.10	Welcome to the Delegates
14.20–14.40	Transplant Innovation & what’s in the Pipeline for the future
14.40–15.20	It’s not just a Software – Match X
15.20–16.00	NGS Solutions – The new kid on the block
16.00–16.20	The Lesser–known Devil – Non HLA

1201

18.00-21.00

Gala Dinner (Councilor and Speaker Plus Guest with ticket)

Time	Subject	Room
8.30-10.00	Plenary Session 5: Solid Organ Transplantation I • Implementation of Virtual Crossmatching in Australia: the laboratory experience Fiona Hudson, Senior Scientist at VTIS, Melbourne, Australia • Determining compatibility in Solid Organ Transplantation – Challenges and Opportunities Rhonda Holdsworth HLA Specialist and Clinical Scientist Specialist Advisor, Transplantation and Immunogenetics Services Pathology and Clinical Governance Division, Australian Red Cross Lifeblood, Australia • Non-HLA antibodies in solid organ transplant Dr. Lucy Sullivan, Scientific Director at Australian Red Cross LifeBlood, Australia
10.00-10.30	Coffee Break with Poster Session III
10.30-12.00	Interactive Session • Case Studies for Complex Patients Assoc. Prof. Duangtawan Thammanichanond, Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand Assoc. Prof. Natavudh Townamchai, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Thailand Dr. Mary Diviney, Senior Clinical Scientist / Manager, Victorian Transplantation and Immunogenetics Service (VTIS), Australian Red Cross Lifeblood, Australia Asst. Prof. Peenida Skulratanasak Division of Nephrology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
12.00-13.00	Lunch
13.00-13.30	Special Lecture by the ASHI President • Expanding Access to Transplantation: Utilization of A2 Kidneys for O and B Recipients Dr. Cathi Murphey, Director, Histocompatibility and Immunogenetics Laboratory, Southwest Immunodiagnostics, Inc.. San Antonio, USA
13.30-14.00	Sponsor Session V (Thermo Fisher): Improving the Efficiency and Reliability of Post-Transplantation Monitoring and Prognosis with Donor-Derived Cell-Free DNA (dd-cfDNA)
14.00-14.30	Short Oral Session III • Identification of Human Leukocyte Antigen mismatches from an in-situ renal allograft biopsy in a patient re-entering the kidney transplant waitlist Mrs. Alicia Crisafio, PathWest Clinical Immunology, Australia • Discrepancy in Deceased Donor Typing Mrs. Arishma Lata, New Zealand Blood Services, New Zealand • Imlifidase desensitization: lab outlooks Dr. Sarah Lloyd, Lifeblood, Australia
14.30-15.00	Coffee Break with Poster Session III
15.00-16.00	Plenary Session 6: Solid Organ Transplantation II • Management of Highly sensitized kidney transplant recipients Prof. Jaeseok Yang, Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital; Laboratory of Transplantation Immunology, Yonsei University Severance Hospital, Korea Prof. Yingyos Avihingsanon, Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Thailand
16.00-16.15	Concluding Remark and Closing